The Spring Vet Visit — What Every Horse Actually Needs and When
The entry form asks for a current Coggins. The show grounds require proof of EHV vaccination. Your barn manager is scheduling the vet and needs to know which horses are due for what. Spring is when the vaccine questions come fast — and the answers matter more than most people realize. Here is exactly what your horse needs, why, and when to schedule it.
There is a particular kind of barn-aisle conversation that happens every March and April, somewhere between the first warm hack and the first show entry. Someone asks whether their horse is due for vaccines. Someone else mentions they heard EHV is going around. A third person is not sure whether their new horse was vaccinated at all before they bought it. And the vet is coming Thursday — but nobody is quite sure what to tell her to bring.
Equine vaccination protocols are not complicated once you understand the framework — but the framework does require understanding. The American Association of Equine Practitioners (AAEP) divides vaccines into two categories: core vaccines, which every horse in North America should receive regardless of lifestyle, and risk-based vaccines, which are recommended based on geographic location, competition schedule, and exposure risk. Both categories matter for the horse that shows. Some of the risk-based vaccines are not optional if you are pulling into a showgrounds in Florida in January or a big indoor in November.
This is the complete spring vaccine guide: what each disease actually does, which vaccines cover it, when they need to be given, and what the show horse's schedule specifically requires.
What Every Horse Needs — No Exceptions
The AAEP's core vaccine list represents the diseases for which vaccination is so critical — due to severity, transmissibility, or zoonotic risk — that no horse should go without them regardless of whether it ever leaves its home farm. These five vaccines form the non-negotiable baseline of every equine health program.
EEE and WEE are mosquito-transmitted viral diseases that cause inflammation of the brain and spinal cord. EEE carries a fatality rate of 75–95% in affected horses; survivors frequently suffer permanent neurological damage. WEE is less lethal but still severe. The Cornell University College of Veterinary Medicine considers EEE one of the most important preventable equine diseases in the eastern United States. Vaccination must be timed to precede mosquito season — in most of the US, that means a spring booster no later than April. In Florida and Gulf Coast states where mosquitoes are year-round, twice-yearly vaccination is recommended.
West Nile Virus, also mosquito-transmitted, emerged in the United States in 1999 and spread rapidly across North America. Approximately 10% of infected horses develop clinical neurological disease; of those, roughly 30–40% die or are euthanized. According to research published by UC Davis School of Veterinary Medicine, annual vaccination with a killed or recombinant WNV vaccine provides reliable protection when timed correctly. The recombinant canarypox-vectored vaccine (Recombitek Equine WNV) has demonstrated strong immunogenicity in studies published in Vaccine.
Clostridium tetani, the bacterium responsible for tetanus, is ubiquitous in soil and produces a neurotoxin that causes progressive, painful muscular rigidity. Horses are among the most susceptible species — significantly more so than cattle or small animals. The fatality rate in unvaccinated horses with clinical tetanus exceeds 80%. Annual vaccination with tetanus toxoid is one of the most straightforward and cost-effective interventions in equine medicine. A booster is also indicated any time a horse sustains a puncture wound, laceration, or undergoes surgery, regardless of when the last annual vaccine was given.
Rabies is invariably fatal once clinical signs appear in any species, including horses. While equine rabies cases are relatively uncommon in the US — the USDA reports approximately 50–60 confirmed cases per year — the zoonotic risk (transmission to humans) makes this a non-negotiable core vaccine. Horses are most commonly exposed through the bite of infected wildlife: raccoons, skunks, foxes, and bats. The Imrab vaccine series is the most widely used in equine practice. Annual vaccination is recommended by the AAEP, AVMA, and public health authorities across North America.
These four vaccines are typically combined with equine herpesvirus in a single appointment and are often administered as combination products — the most common being Fluvac Innovator EHV-1,4 or Prestige V + WNV — which reduces the number of injections while covering multiple diseases. Your veterinarian will advise on which combination products are available and appropriate for your horse's history.
What the Show Horse Needs — Beyond the Baseline
For horses that compete, travel, or live in barns with regular equine traffic, the core vaccine list is the floor, not the ceiling. The following risk-based vaccines are effectively mandatory for any horse participating in the hunter/jumper or warmblood sport horse world — not because the AAEP requires them, but because the diseases they prevent spread with devastating speed through show environments, and because many showgrounds and competitions require proof of vaccination as a condition of entry.
EHV-1 and EHV-4 are among the most prevalent respiratory viruses in the equine population worldwide. EHV-4 causes primarily respiratory disease — the "rhinopneumonitis" that spreads rapidly through show barns. EHV-1 is more serious: in addition to respiratory disease, it causes abortion in pregnant mares and, in its neurological form (EHM — equine herpesvirus myeloencephalopathy), causes progressive hindlimb ataxia, bladder dysfunction, and in severe cases, inability to rise. Dr. Lutz Goehring of Ludwig Maximilian University Munich, a leading European EHV researcher, has noted that the neurological form of EHV-1 appears to be increasing in frequency in the European competition horse population. The FEI and most major European show organizers now require documented EHV vaccination within 6 months as a condition of entry. Available vaccines in the US include Rhinomune, Pneumabort-K, and the Prestige series. No currently available vaccine fully prevents EHM, but vaccination significantly reduces viral shedding and transmission.
Equine influenza is the most common infectious respiratory disease of horses worldwide. The virus — H3N8 subtype — spreads via aerosolized respiratory secretions with extraordinary efficiency: a single infected horse can expose every horse within a 50-meter radius. The 2007 Australian equine influenza outbreak, which infected over 76,000 horses in a previously naive population, demonstrated the catastrophic potential of the disease in unvaccinated herds. Research from the Animal Health Trust in Newmarket, UK — one of Europe's leading equine disease research centers — has demonstrated that modified live intranasal vaccines (Flu Avert I.N.) produce faster mucosal immunity than killed injectable vaccines, making them particularly valuable in the two to three weeks before a horse's first show of the season. The FEI requires EIV vaccination within 6 months of competition. USEF rules require vaccination within 6 months for horses entering most sanctioned competitions.
Strangles — caused by Streptococcus equi subsp. equi — is the most frequently diagnosed infectious disease of horses worldwide, according to a landmark epidemiological study published in Equine Veterinary Journal in 2014. The disease causes dramatic lymph node abscessation, high fever, and nasal discharge; in its bastard or metastatic form, abscesses can form in internal organs with potentially fatal consequences. The intranasal modified live vaccine (Pinnacle I.N.) stimulates mucosal immunity at the site of natural infection and is generally preferred over the killed injectable (Strepvax II) for horses with high exposure risk. Important caveat: horses that have recently recovered from strangles or that are carriers of S. equi should not be vaccinated without veterinary guidance — vaccination of a carrier horse can trigger purpura hemorrhagica, a serious immune-mediated complication.
Potomac Horse Fever (PHF) is a seasonal disease caused by the rickettsial organism Neorickettsia risticii, transmitted through the ingestion of aquatic insects carrying infected trematode larvae — most commonly caddisflies and mayflies attracted to barn lights near rivers and streams. Clinical signs include fever, depression, severe watery to projectile diarrhea, and laminitis in a significant proportion of affected horses. Case fatality rates of 5–30% have been reported. The disease is endemic in the mid-Atlantic, upper Midwest, and parts of California. Research from Cornell's College of Veterinary Medicine has documented its spread into previously unaffected regions. Vaccination with the killed whole-cell bacterin provides moderate protection; because Neorickettsia strains vary geographically, vaccine efficacy varies by region. Annual spring vaccination is recommended in endemic areas, with a booster in late summer in high-risk locations.
Leptospirosis in horses is caused by several serovars of Leptospira interrogans, most commonly Pomona and Grippotyphosa. The disease is transmitted through contact with water, soil, or feed contaminated by the urine of infected wildlife — primarily deer, raccoons, and rodents. In horses, leptospirosis is a leading cause of recurrent uveitis (moon blindness), a progressive inflammatory eye condition that is the most common cause of blindness in horses worldwide. Research from Tierärztliche Hochschule Hannover (University of Veterinary Medicine Hannover) has established the link between specific Leptospira serovars and equine recurrent uveitis in the European warmblood population. The Lepto EQ Innovator vaccine, licensed in the US, covers the Pomona and Grippotyphosa serovars most commonly implicated in equine disease. Annual vaccination is recommended for horses with regular pasture access, particularly those near wildlife corridors or standing water.
Clostridium botulinum produces one of the most potent neurotoxins known. In horses, botulism most commonly results from ingestion of the toxin in contaminated feed — particularly haylage, big bale silage, and round bales where anaerobic conditions allow Clostridium to proliferate. Type B botulism is the predominant form in the eastern United States; Type C occurs in the Midwest and West. Clinical signs progress from muscle weakness and difficulty swallowing to recumbency and respiratory failure. The Botumune (BotVax B) vaccine provides protection against Type B toxin and is strongly recommended for any horse fed preserved forages. Dr. Monica Aleman of UC Davis's Large Animal Neurology and Neurosurgery service notes that botulism is frequently underdiagnosed in horses because early signs — mild muscle trembling, difficulty picking up feed — are easily attributed to other causes.
Timing the Spring Vaccine Appointment for Competition
For the horse that competes, vaccine timing is not just a health decision — it is a logistics decision. Vaccines administered too close to a competition can cause transient reactions (mild fever, localized swelling, reduced performance) that interfere with preparation. Vaccines administered too late in the season fail to provide peak immunity when exposure risk is highest. Getting this timing right requires working backward from your first show date rather than forward from whenever the vet is available.
8–10 weeks before first show: Schedule the appointment. This gives adequate time to rebook if your horse has a reaction and to ensure the full immune response has developed before competition begins. Dr. Kate Chope, equine internal medicine specialist and former FEI treating veterinarian, recommends building at minimum a two-week buffer between the last vaccine and the first competition day.
6–8 weeks before first show: Administer core vaccines (EEE/WEE, WNV, tetanus, rabies) and EHV/EIV. If your horse is on a biannual EHV/EIV schedule, ensure the spring booster falls within the six-month window required by USEF and FEI rules. Horses that have not been vaccinated previously for a given disease will require a two-dose primary series administered 3–4 weeks apart — factor this into your timeline.
4 weeks before first show: If administering strangles intranasally (Pinnacle I.N.), this is the appropriate timing window. Do not give intranasal strangles at the same appointment as injectable vaccines — administer them separately by at least one week.
2 weeks before first show: Last acceptable date for any vaccine administration for horses with a history of post-vaccine reactions. For horses with no reaction history, the two-week window provides adequate time for immune response development.
How Vaccination Protocols Differ Across the Atlantic
The hunter/jumper and warmblood sport horse worlds are genuinely international, and horses that compete in Europe or are imported from European breeding programs may have vaccination histories that look quite different from the standard US protocol. Understanding these differences matters both for newly imported horses and for horses that travel internationally to compete.
The FEI's mandatory vaccination requirements — which govern all FEI-sanctioned competition globally — currently require equine influenza vaccination within 6 months of competition, with a booster given between 7 and 180 days before the event. EHV vaccination is strongly recommended by the FEI and required by many national federations and individual show organizers across Europe, though it remains advisory rather than mandatory at FEI level. The European requirement for EHV documentation has become significantly more stringent since the 2021 EHV-1 outbreak at the Valencia CSI5* in Spain, which resulted in the death of eleven horses and the quarantine of over 700.
The Faculty of Veterinary Medicine at Ghent University in Belgium — one of Europe's leading equine research institutions — has published extensively on the immunogenicity of EHV vaccines in sport horses, noting that the six-month booster interval recommended by most manufacturers may be insufficient for horses with very high exposure risk, such as those competing weekly at international level. Some European sport horse vets have moved to a four-month interval for their elite competition horses as a result.
Horses imported from Europe will typically have received EHV and EIV vaccines on the European schedule, which may use different products than those available in the US. The most commonly used EHV vaccine in continental Europe is Equip EHV 1,4 (Zoetis), which is not licensed in the US. Your veterinarian will need to review the import health records carefully and establish a US-compatible schedule from the point of arrival.
Equine Viral Arteritis (EVA). EVA is a notifiable disease in the United States and a significant biosecurity concern at international competitions. Caused by equine arteritis virus, it spreads via respiratory secretions and venereal transmission. Stallions can become persistently infected shedders. Vaccination exists (Artervac, not licensed in all US states) and is required for breeding stallions in many European countries. Horses importing into or exporting from the US require EVA testing — your veterinarian and a USDA accredited vet must be involved.
African Horse Sickness (AHS). Not present in North America but endemic in sub-Saharan Africa and with documented incursions into Spain and Portugal. Any horse traveling to or competing in southern Europe should have current information on AHS status in the region. Vaccination is available in affected regions.
Glanders and Dourine. Rare but notifiable diseases that appear on international health certificate requirements for horses moving between countries. US horses traveling to Europe will require documentation confirming freedom from both conditions as part of the export health certificate process.
What to Tell Your Veterinarian — and What to Keep in Your Records
The single most useful thing you can do before the spring vet appointment is have your horse's complete vaccination history available. This sounds obvious but is frequently not the case — horses change hands, barn managers change, and vaccine records get lost with surprising regularity. A horse whose history is unknown should be treated as unvaccinated and started on a primary series for each core and risk-based vaccine, which affects both timing and cost.
USEF and FEI both accept paper vaccination records signed and stamped by a licensed veterinarian. Keep a copy in your tack trunk, a copy at home, and a photo on your phone. The FEI has moved toward digital vaccination recording via the FEI HorseApp, which allows vaccination records to be verified at the gate — if your horse competes internationally, register it on the app and ensure your veterinarian records each vaccination digitally. Several major US horse shows are beginning to accept FEI HorseApp records in place of paper.
USEF's general rules require EIV/EHV vaccination within 6 months for horses entering most sanctioned competitions, but individual show managers can and do impose additional requirements. The Winter Equestrian Festival in Wellington, the Devon Horse Show, and the Hampton Classic all publish specific health requirements in their prize lists — read them each year, as they change. Arriving at the gate with documentation that does not meet the current requirements is an entirely avoidable crisis.
Administering vaccines to a horse that is febrile, immunocompromised, or recovering from illness reduces vaccine efficacy and can exacerbate the underlying condition. The immune system is already engaged — adding the antigenic load of multiple vaccines simultaneously competes for the immune response rather than building on it. If your horse is unwell at the scheduled appointment, postpone the vaccines. Your veterinarian will advise on the appropriate waiting period based on the specific condition.
Most horses tolerate vaccination well. Mild reactions — localized swelling and soreness at the injection site, low-grade fever for 24–48 hours, reduced energy — are common and self-limiting. More significant reactions — fever above 103°F (39.4°C), pronounced swelling, difficulty breathing, hives, or anaphylaxis — require immediate veterinary attention. Dr. Nicola Pusterla of UC Davis advises keeping horses under observation for at least 30–60 minutes after vaccination and rechecking temperature 12 and 24 hours post-injection during high-risk periods.
The immune response to vaccination is metabolically active — the body is doing work. Strenuous exercise in the 24–48 hours following vaccination has been shown in research from the Royal Veterinary College London to transiently suppress immune response development, potentially reducing the efficacy of the vaccine. Light hacking, hand-walking, or turnout is appropriate in the two days following a vaccine appointment. Resume normal training on day three unless your horse is showing signs of a reaction.
"Vaccination is the most cost-effective medicine in the barn. The diseases it prevents cost far more — in money, in horses, and in time — than the appointment it requires."
— The Editorial, Notting Hill EquineThe spring vet appointment is not the most glamorous part of the season. It does not feel like preparation the way a new saddle pad does, or a lesson with a clinician, or the first gallop on firm ground after a winter of indoor work. But it is the preparation that makes everything else possible — the foundation beneath the show schedule, the entry form, the early morning hack down a road that is finally dry. Book it early. Get it right. Then go ride.
0 comments